Diabetes

November 25, 2020

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

November 25, 2020

In the last of our 3-part series examining the idea of a cardiometabolic subspecialty, Simon Murray, MD, offers his thoughts on who should be treating patients with type 2 diabetes.

November 24, 2020

An endocrinologist from Brigham and Women’s Hospital discusses the latest in diabetes management.

November 23, 2020

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

November 21, 2020

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

November 19, 2020

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

November 18, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

November 18, 2020

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

November 17, 2020

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

November 16, 2020

Pooled analysis of SUSTAIN 6 and PIONEER 6 trials indicates the impact of semaglutide impact on MACE was present regardless of baseline triglyceride levels among diabetic patients.